June 15, 2022 -- Bruker has announced large field-of-view highly multiplexed immunohistochemistry based on matrix-assisted laser desorption/ionization (MALDI HiPLEX-IHC) imaging of targeted proteins, overlaid with unbiased small molecule MALDI imaging on fresh frozen or formalin fixed paraffin embedded (FFPE) tissues, for spatial biology and cancer research.
According to the company, MALDI HiPLEX-IHC is a breakthrough in multiomics imaging by combining targeted protein expression spatial profiling with unbiased small molecule MALDI imaging to co-localize proteins and small molecules such as glycans, lipids, metabolites, or xenobiotics.
In addition to mapping tens to over 100 targeted proteins with high-plex peptide tags, MALDI HiPLEX-IHC can track signaling pathways such as glycosylation, observe lipid spatial profiles for tumor microenvironment segmentation, or simultaneously observe how drugs affect both protein and metabolic states.
"From the perspective of a lab heavily invested in cellular signaling processes in cancer biology, MALDI HiPLEX-IHC is a game changer allowing integration of mass spectrometry imaging with cell biology. We will be using this technology for multiomic N-glycan and collagen imaging studies to understand aggressive breast cancers," said Peggi Angel, PhD, professor of cell and molecular pharmacology and experimental therapeutics at the Medical University of South Carolina.